International Society Of Neuropathology--Haarlem consensus guidelines for nervous system tumor classification and grading

David N. Louis, Arie Perry, Peter Burger, David W. Ellison, Guido Reifenberger, Andreas von Deimling, Kenneth Aldape, Daniel Brat, V. Peter Collins, Charles Eberhart, Dominique Figarella-Branger, Gregory N. Fuller, Felice Giangaspero, Caterina Giannini, Cynthia Hawkins, Paul Kleihues, Andrey Korshunov, Johan M. Kros, M. Beatriz Lopes, Ho Keung Ng & 8 others Hiroko Ohgaki, Werner Paulus, Torsten Pietsch, Marc Rosenblum, Elisabeth Rushing, Figen Soylemezoglu, Otmar Wiestler, Pieter Wesseling

Research output: Contribution to journalArticle

Abstract

Major discoveries in the biology of nervous system tumors have raised the question of how non-histological data such as molecular information can be incorporated into the next World Health Organization (WHO) classification of central nervous system tumors. To address this question, a meeting of neuropathologists with expertise in molecular diagnosis was held in Haarlem, the Netherlands, under the sponsorship of the International Society of Neuropathology (ISN). Prior to the meeting, participants solicited input from clinical colleagues in diverse neuro-oncological specialties. The present "white paper" catalogs the recommendations of the meeting, at which a consensus was reached that incorporation of molecular information into the next WHO classification should follow a set of provided "ISN-Haarlem" guidelines. Salient recommendations include that (i) diagnostic entities should be defined as narrowly as possible to optimize interobserver reproducibility, clinicopathological predictions and therapeutic planning; (ii) diagnoses should be "layered" with histologic classification, WHO grade and molecular information listed below an "integrated diagnosis"; (iii) determinations should be made for each tumor entity as to whether molecular information is required, suggested or not needed for its definition; (iv) some pediatric entities should be separated from their adult counterparts; (v) input for guiding decisions regarding tumor classification should be solicited from experts in complementary disciplines of neuro-oncology; and (iv) entity-specific molecular testing and reporting formats should be followed in diagnostic reports. It is hoped that these guidelines will facilitate the forthcoming update of the fourth edition of the WHO classification of central nervous system tumors.

Original languageEnglish
Pages (from-to)429-435
Number of pages7
JournalBrain Pathology
Volume24
Issue number5
DOIs
Publication statusPublished - Sep 1 2014

Fingerprint

Nervous System Neoplasms
Neoplasm Grading
Guidelines
Central Nervous System Neoplasms
Netherlands
Neoplasms
Neuropathology
Pediatrics

Keywords

  • Astrocytoma
  • atypical teratoid rhabdoid tumor
  • brain tumors
  • classification
  • glioblastoma
  • glioma
  • grading
  • medulloblastoma
  • oligodendroglioma
  • World Health Organization

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Louis, D. N., Perry, A., Burger, P., Ellison, D. W., Reifenberger, G., von Deimling, A., ... Wesseling, P. (2014). International Society Of Neuropathology--Haarlem consensus guidelines for nervous system tumor classification and grading. Brain Pathology, 24(5), 429-435. https://doi.org/10.1111/bpa.12171

International Society Of Neuropathology--Haarlem consensus guidelines for nervous system tumor classification and grading. / Louis, David N.; Perry, Arie; Burger, Peter; Ellison, David W.; Reifenberger, Guido; von Deimling, Andreas; Aldape, Kenneth; Brat, Daniel; Collins, V. Peter; Eberhart, Charles; Figarella-Branger, Dominique; Fuller, Gregory N.; Giangaspero, Felice; Giannini, Caterina; Hawkins, Cynthia; Kleihues, Paul; Korshunov, Andrey; Kros, Johan M.; Beatriz Lopes, M.; Ng, Ho Keung; Ohgaki, Hiroko; Paulus, Werner; Pietsch, Torsten; Rosenblum, Marc; Rushing, Elisabeth; Soylemezoglu, Figen; Wiestler, Otmar; Wesseling, Pieter.

In: Brain Pathology, Vol. 24, No. 5, 01.09.2014, p. 429-435.

Research output: Contribution to journalArticle

Louis, DN, Perry, A, Burger, P, Ellison, DW, Reifenberger, G, von Deimling, A, Aldape, K, Brat, D, Collins, VP, Eberhart, C, Figarella-Branger, D, Fuller, GN, Giangaspero, F, Giannini, C, Hawkins, C, Kleihues, P, Korshunov, A, Kros, JM, Beatriz Lopes, M, Ng, HK, Ohgaki, H, Paulus, W, Pietsch, T, Rosenblum, M, Rushing, E, Soylemezoglu, F, Wiestler, O & Wesseling, P 2014, 'International Society Of Neuropathology--Haarlem consensus guidelines for nervous system tumor classification and grading', Brain Pathology, vol. 24, no. 5, pp. 429-435. https://doi.org/10.1111/bpa.12171
Louis, David N. ; Perry, Arie ; Burger, Peter ; Ellison, David W. ; Reifenberger, Guido ; von Deimling, Andreas ; Aldape, Kenneth ; Brat, Daniel ; Collins, V. Peter ; Eberhart, Charles ; Figarella-Branger, Dominique ; Fuller, Gregory N. ; Giangaspero, Felice ; Giannini, Caterina ; Hawkins, Cynthia ; Kleihues, Paul ; Korshunov, Andrey ; Kros, Johan M. ; Beatriz Lopes, M. ; Ng, Ho Keung ; Ohgaki, Hiroko ; Paulus, Werner ; Pietsch, Torsten ; Rosenblum, Marc ; Rushing, Elisabeth ; Soylemezoglu, Figen ; Wiestler, Otmar ; Wesseling, Pieter. / International Society Of Neuropathology--Haarlem consensus guidelines for nervous system tumor classification and grading. In: Brain Pathology. 2014 ; Vol. 24, No. 5. pp. 429-435.
@article{4b012ffeb24b499c9a6375f803c517cb,
title = "International Society Of Neuropathology--Haarlem consensus guidelines for nervous system tumor classification and grading",
abstract = "Major discoveries in the biology of nervous system tumors have raised the question of how non-histological data such as molecular information can be incorporated into the next World Health Organization (WHO) classification of central nervous system tumors. To address this question, a meeting of neuropathologists with expertise in molecular diagnosis was held in Haarlem, the Netherlands, under the sponsorship of the International Society of Neuropathology (ISN). Prior to the meeting, participants solicited input from clinical colleagues in diverse neuro-oncological specialties. The present {"}white paper{"} catalogs the recommendations of the meeting, at which a consensus was reached that incorporation of molecular information into the next WHO classification should follow a set of provided {"}ISN-Haarlem{"} guidelines. Salient recommendations include that (i) diagnostic entities should be defined as narrowly as possible to optimize interobserver reproducibility, clinicopathological predictions and therapeutic planning; (ii) diagnoses should be {"}layered{"} with histologic classification, WHO grade and molecular information listed below an {"}integrated diagnosis{"}; (iii) determinations should be made for each tumor entity as to whether molecular information is required, suggested or not needed for its definition; (iv) some pediatric entities should be separated from their adult counterparts; (v) input for guiding decisions regarding tumor classification should be solicited from experts in complementary disciplines of neuro-oncology; and (iv) entity-specific molecular testing and reporting formats should be followed in diagnostic reports. It is hoped that these guidelines will facilitate the forthcoming update of the fourth edition of the WHO classification of central nervous system tumors.",
keywords = "Astrocytoma, atypical teratoid rhabdoid tumor, brain tumors, classification, glioblastoma, glioma, grading, medulloblastoma, oligodendroglioma, World Health Organization",
author = "Louis, {David N.} and Arie Perry and Peter Burger and Ellison, {David W.} and Guido Reifenberger and {von Deimling}, Andreas and Kenneth Aldape and Daniel Brat and Collins, {V. Peter} and Charles Eberhart and Dominique Figarella-Branger and Fuller, {Gregory N.} and Felice Giangaspero and Caterina Giannini and Cynthia Hawkins and Paul Kleihues and Andrey Korshunov and Kros, {Johan M.} and {Beatriz Lopes}, M. and Ng, {Ho Keung} and Hiroko Ohgaki and Werner Paulus and Torsten Pietsch and Marc Rosenblum and Elisabeth Rushing and Figen Soylemezoglu and Otmar Wiestler and Pieter Wesseling",
year = "2014",
month = "9",
day = "1",
doi = "10.1111/bpa.12171",
language = "English",
volume = "24",
pages = "429--435",
journal = "Brain Pathology",
issn = "1015-6305",
publisher = "Wiley-Blackwell",
number = "5",

}

TY - JOUR

T1 - International Society Of Neuropathology--Haarlem consensus guidelines for nervous system tumor classification and grading

AU - Louis, David N.

AU - Perry, Arie

AU - Burger, Peter

AU - Ellison, David W.

AU - Reifenberger, Guido

AU - von Deimling, Andreas

AU - Aldape, Kenneth

AU - Brat, Daniel

AU - Collins, V. Peter

AU - Eberhart, Charles

AU - Figarella-Branger, Dominique

AU - Fuller, Gregory N.

AU - Giangaspero, Felice

AU - Giannini, Caterina

AU - Hawkins, Cynthia

AU - Kleihues, Paul

AU - Korshunov, Andrey

AU - Kros, Johan M.

AU - Beatriz Lopes, M.

AU - Ng, Ho Keung

AU - Ohgaki, Hiroko

AU - Paulus, Werner

AU - Pietsch, Torsten

AU - Rosenblum, Marc

AU - Rushing, Elisabeth

AU - Soylemezoglu, Figen

AU - Wiestler, Otmar

AU - Wesseling, Pieter

PY - 2014/9/1

Y1 - 2014/9/1

N2 - Major discoveries in the biology of nervous system tumors have raised the question of how non-histological data such as molecular information can be incorporated into the next World Health Organization (WHO) classification of central nervous system tumors. To address this question, a meeting of neuropathologists with expertise in molecular diagnosis was held in Haarlem, the Netherlands, under the sponsorship of the International Society of Neuropathology (ISN). Prior to the meeting, participants solicited input from clinical colleagues in diverse neuro-oncological specialties. The present "white paper" catalogs the recommendations of the meeting, at which a consensus was reached that incorporation of molecular information into the next WHO classification should follow a set of provided "ISN-Haarlem" guidelines. Salient recommendations include that (i) diagnostic entities should be defined as narrowly as possible to optimize interobserver reproducibility, clinicopathological predictions and therapeutic planning; (ii) diagnoses should be "layered" with histologic classification, WHO grade and molecular information listed below an "integrated diagnosis"; (iii) determinations should be made for each tumor entity as to whether molecular information is required, suggested or not needed for its definition; (iv) some pediatric entities should be separated from their adult counterparts; (v) input for guiding decisions regarding tumor classification should be solicited from experts in complementary disciplines of neuro-oncology; and (iv) entity-specific molecular testing and reporting formats should be followed in diagnostic reports. It is hoped that these guidelines will facilitate the forthcoming update of the fourth edition of the WHO classification of central nervous system tumors.

AB - Major discoveries in the biology of nervous system tumors have raised the question of how non-histological data such as molecular information can be incorporated into the next World Health Organization (WHO) classification of central nervous system tumors. To address this question, a meeting of neuropathologists with expertise in molecular diagnosis was held in Haarlem, the Netherlands, under the sponsorship of the International Society of Neuropathology (ISN). Prior to the meeting, participants solicited input from clinical colleagues in diverse neuro-oncological specialties. The present "white paper" catalogs the recommendations of the meeting, at which a consensus was reached that incorporation of molecular information into the next WHO classification should follow a set of provided "ISN-Haarlem" guidelines. Salient recommendations include that (i) diagnostic entities should be defined as narrowly as possible to optimize interobserver reproducibility, clinicopathological predictions and therapeutic planning; (ii) diagnoses should be "layered" with histologic classification, WHO grade and molecular information listed below an "integrated diagnosis"; (iii) determinations should be made for each tumor entity as to whether molecular information is required, suggested or not needed for its definition; (iv) some pediatric entities should be separated from their adult counterparts; (v) input for guiding decisions regarding tumor classification should be solicited from experts in complementary disciplines of neuro-oncology; and (iv) entity-specific molecular testing and reporting formats should be followed in diagnostic reports. It is hoped that these guidelines will facilitate the forthcoming update of the fourth edition of the WHO classification of central nervous system tumors.

KW - Astrocytoma

KW - atypical teratoid rhabdoid tumor

KW - brain tumors

KW - classification

KW - glioblastoma

KW - glioma

KW - grading

KW - medulloblastoma

KW - oligodendroglioma

KW - World Health Organization

UR - http://www.scopus.com/inward/record.url?scp=84933520969&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84933520969&partnerID=8YFLogxK

U2 - 10.1111/bpa.12171

DO - 10.1111/bpa.12171

M3 - Article

VL - 24

SP - 429

EP - 435

JO - Brain Pathology

JF - Brain Pathology

SN - 1015-6305

IS - 5

ER -